drugset

drugset / Trial / NCT00408395

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

NCT00408395 ↗

Phase 2 Completed 281 enrolled Novartis Vaccines

RandomizedParallel-groupSingle-blindPrevention

Summary

This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.

Timeline

Start: 2006-11
Primary completion: 2007-08
Completion: 2007-08

Publications

Results Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Influenza Virus Vaccine	Vaccine	0.25 ml	Intramuscular

Indications